For small and mid-size pharma companies, launch readiness is often framed around what they lack: infrastructure, headcount, and the ability to invest at the scale of larger organizations. At the Indegene Digital Summit 2026, Archana Sondhi of IDEAYA Biosciences, Ambaw Bellete, formerly of CG Oncology, and Bryan Downey of Cingulate Inc. offered a different view. A focused pharma launch strategy can turn size into an advantage by forcing sharper choices about where to invest, which pre-launch activities matter most, and when the organization has earned the right to scale.
Turn Constraints Into Focus
Limited resources can create useful discipline. Smaller organizations cannot invest everywhere at once, which makes prioritization essential and can also enable faster decision-making. For a first launch, that may mean concentrating field effort on priority accounts, using inside sales to cover white space, and applying digital engagement to extend reach before committing to a much larger field footprint. The objective is not to under-resource the launch, but to sequence investment around where it can create value first.
Bryan Downey captured the distinction clearly: "Being small does not necessarily mean being lean. It means being focused." The opportunity is not to recreate big pharma with fewer people, but to design the launch around the capabilities that matter most and expand as evidence builds.
Start With the Problem, Not The Technology
AI featured prominently in the discussion, but the panel resisted treating it as an end in itself. The stronger starting point is to identify the problem that needs solving, then determine whether AI can improve the answer. Archana Sondhi pointed to examples such as adding digital behavior to physician segmentation, using predictive data to improve patient identification in rare oncology, and helping field teams prepare for different customer archetypes. These applications are useful because they sharpen a specific decision, not because they add another technology layer.
The same logic can support more informed account planning by bringing together prescribing, access, refill, and engagement signals. For resource-constrained organizations, better decisions can substitute for brute-force scale.
Build Launch Readiness Earlier Than You Think
The discussion also challenged the idea that omnichannel, content, data, and commercial infrastructure should wait until approval is close. Commercial expertise often needs to enter earlier, particularly as an asset moves through later-stage development. The right timing depends on the market: a crowded indication may require earlier patient and clinician activation, while a rare-disease launch may need more time to identify a small number of patients and treating physicians.
Teams also benefit from having time to learn before day one. Several months of behavioral data can help validate assumptions, refine targeting, and identify what needs to change before the commercial engine is fully activated. That is a more useful definition of launch readiness than simply having systems in place. Pre-launch activities should create learning, so the organization enters launch with a clearer view of who matters, how those customers engage, and which channels are most likely to work.
The same principle applies to search visibility. If AI-driven discovery will influence how healthcare professionals find information, generative engine optimization should be considered before launch rather than added later. Building the content foundation early can improve visibility when the product reaches market.
Be Deliberate About What Stays Inside
The build-versus-buy discussion was less about outsourcing and more about strategic ownership. Strategy and the capabilities that create competitive advantage should remain close to the organization, while partners can help provide specialist expertise, execution capacity, and scale. The internal team still needs enough knowledge to direct the work, challenge assumptions, and understand what good execution looks like.
For smaller pharma companies, that is more useful than simply asking what can be outsourced. The question is which capabilities differentiate the company or asset, and which can be accessed more efficiently through partners.
Move Beyond the Big-Bang Launch
The final challenge to the traditional pharma launch strategy was the assumption that every element of commercialization must be fully built for one launch moment. Downey argued for a more progressive model: do a smaller number of things exceptionally well, learn as access and demand develop, and then “earn the scale” before expanding quickly.
That reframes launch readiness for smaller companies. The goal is not to imitate the machinery of larger pharma, but to prepare earlier, prioritize harder, and scale where evidence supports it. A launch model built around focus, learning, and staged investment can give small and mid-size companies a way to compete without losing the agility that made them different in the first place.